There is a real need for new treatment options for the complications of #Crohns disease. TiGenix is committed to working to bring innovative new medicines to patients #WorldIBDDay
Maria Pascual, VP Regulatory Affairs and Corporate Quality at TiGenix: “Today’s approval reflects our deep understanding and recognized leadership in the development of allogeneic stem cells and our firm commitment to developing innovative therapies for medical needs.” #crohns
[VIDEO] TiGenix focuses on the anti-inflammatory properties of adipose-derived stem cells to make new therapies. Discover how it works
youtu.be/En4dcUgLqpI via @YouTube
-There is a real need for new treatment options for the complications of #Crohns disease. TiGenix is committed to working to bring innovative new medicines to patients #CCAwarenessWeek#IBD@CrohnsColitisFn